P-1077. Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam (C/T) Real-world Analysis (SPECTRA): Clinical Outcomes and Treatment Patterns from Mexico

Abstract Background Reported are results of SPECTRA data from Mexico Methods SPECTRA (n=617) is a 7-country multicentre retrospective observational study, including hospitalized adult patients (≥18 years) treated with C/T for ≥48 hours. Medical records were reviewed for 30 days after the last dose of C/T or until death. Reported are clinical outcomes and treatment patterns in Mexico.Table 2.All-cause in-hospital mortality (ACHM) in the Mexico cohort Results Mean age of patients (n=59) is 55.2 years, and 47.5% were female. Common comorbidities were diabetes mellitus (DM) uncomplicated (18.6%) and DM with end organ damage (3.4%), transplantation (16.9%), heart disease (16.9%), chronic kidney disease (11.9%), chronic pulmonary disease (10.2%), acute kidney injury (10.2%), and end-stage renal disease (3.4%). From positive cultures (n=32) were found 21 multi-drug resistant (MDR) Pseudomonas aeruginosa (PsA) (65.6%) and 4 MDR Enterbacterecea (12.5%). C/T was used to treat pneumonia (30/59, 50.8%), complicated intra-abdominal infection (9/59,15.3%), complicated urinary tract infection (8/59, 13.6%), bone and joint infection (8/59, 13.6%), and sepsis (8/59, 13.6%). Mean time from the index hospitalization admission to C/T initiation is 16.0 days. Mean time from the first microbiology (MB) sample for the index infection to C/T initiation is 1.9 days. C/T treatment duration was median 8.0 days (Q1:Q3; 5, 11). Doses included 54.2% 1.5g/Q8h; 39.0% 3g/Q8h; 5.1% 750mg/Q8h; 1.7% 1g/Q8h. C/T rank of initiations: first-line (49.2%), second-line (42.4%), third-line (6.8%), fourth-line (0), fifth-line (1.7%), sixth+line (0). Of all the cases, empiric therapy accounted for (37/59) 62.7%, definitive therapy in (17/59) 28.8%, and undetermined (5/59) (8.5%). Clinical success rate for treating the index infection with C/T is 79.7% of patients (Table 1). All-Cause-Hospital-Mortality (ACHM) is 16.9%. Median time from index date to death is 12.0 days (Table 2). ICU admission is reported in 42.4% of cases, with a median ICU length of stay at 20.0 days (Table 3).Table 3.ICU admission and LOS during the index hospitalisation from the Mexico† ICU LOS if ICU admission was related to index infection.CI, confidence interval; ICU, intensive care unit; LOS, length of stay; SD, standard deviation. Conclusion Results show real-world effectiveness of C/T in Mexico, more research is warranted. Disclosures Yanbing Zhou, PhD, Merck: I am a full time Merck Employee and own stocks in the retirement plan provided by Merck.|Merck: Stocks/Bonds (Public Company) Thales Polis, MD, MSD: Stocks/Bonds (Public Company) Emre Yucel, PhD, Merck: I am a full time Merck Employee and own stocks in the retirement plan provided by Merck.|Merck: Stocks/Bonds (Public Company)